ArticleInsights into imaging2025
Quantitative assessment of hepatic steatosis by ultrasound-guided attenuation parameter in patients with impaired glucose tolerance.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thermoacoustic Ultrasound Assessment of Liver Steatosis-A Novel Approach for MASLD Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOur objective was to provide further evidence regarding the diagnostic accuracy of ultrasound-guided attenuation parameter (UGAP) for detecting hepatic steatosis in a selected and homogeneous cohort of patients with impaired glucose tolerance using magnetic resonance imaging-proton density fat fraction (MRI-PDFF) as the standard reference method. MATERIALS AND
methodsFrom October 2023 to March 2024, individuals with impaired glucose tolerance and suspected metabolic dysfunction-associated steatotic liver disease (MASLD) who underwent abdominal ultrasound and MRI-PDFF were enrolled in this prospective study. Multivariable linear regression was performed to assess independent factors associated with UGAP. The correlation between UGAP, and MRI-PDFF was evaluated using the Pearson correlation coefficient. The diagnostic performance of the UGAP for hepatic steatosis was assessed using the area under the receiver operating characteristic curve (AUC).
resultsA total of 193 participants (median age, 35 years; IQR, 25-48 years; 98 male) were evaluated, including 90 participants (47%) with MASLD. Body mass index (BMI), waist circumference, and skin-liver capsule distance were independently associated with UGAP. UGAP was strongly and positively correlated with MRI-PDFF (r = 0.890, p < 0.001). The AUCs of UGAP for diagnosing hepatic steatosis ≥ S1 (MRI-PDFF ≥ 6.4%), ≥ S2 (MRI-PDFF ≥ 17.4%), and ≥ S3 (MRI-PDFF ≥ 22.1%) were 0.980 (95% CI: 0.957-1.000), 0.955 (95% CI: 0.912-0.999), and 0.985 (95% CI: 0.970-1.000), respectively.
conclusionsUGAP could accurately diagnose hepatic steatosis and estimate the hepatic fat fraction. CRITICAL RELEVANCE STATEMENT: UGAP has high diagnostic performance for hepatic steatosis. UGAP offers a method of quantifying liver fat content similar to MRI-PDFF, which is anticipated to be beneficial in the long-term monitoring of patients with impaired glucose tolerance. KEY POINTS: Hepatic steatosis is an early factor that causes liver damage in MASLD. UGAP has an accurate diagnostic performance for hepatic steatosis. UGAP was positively correlated with MRI- proton density fat fraction. Some clinical parameters may affect UGAP measurement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.